Improving Memory in Patients With Multiple Sclerosis

Withdrawn before enrolling · Phase 3

Conditions studied: Multiple Sclerosis

In brief

People with multiple sclerosis (MS) suffer from cognitive and other brain problems. This study will examine the effectiveness of the drug donepezil and of sugar water for enhancing memory in individuals with MS. Donepezil (also known as Aricept) has been FDA approved for improving memory and learning in individuals with Alzheimer's disease.

Key facts

Study ID: NCT00062972
Run by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
People needed: 0
Starts: 1999-09-01
Expected to finish: 2002-08-01
Last updated by the study team: 2017-04-25

Who can join

Age: 18 and older, up to 56. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

MS as defined by the Poser criteria
Expanded Disability Status Scale (EDSS) score of 0 to 6.5
Stable neurologic function for at least 30 days prior to study entry
Agree to continue all current medications for study duration
Rey Auditory Verbal Learning Test score in low normal range or below
Mini-mental status exam score of 26 or higher
Montgomery-Asberg Depression Scale scaled score of 14 or lower
Fluent in English

You may not qualify if…

Use of anticholinergic or benzodiazepine medication
Change in dosage of medications judged to have the potential to impact cognitive function (e.g., antispasticity medications) within 2 weeks of study entry
Current alcohol or substance abuse
History of neurological or major medical problem that has a known effect on cognitive functioning
History of noncompliance
Visual or upper extremity impairment which precludes ability to participate in cognitive assessment

Where it is running

University Hospital and Medical Center — Stony Brook, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.